Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
0.9100
+0.0200 (2.25%)
Jul 24, 2025, 3:08 PM - Market open
Cue Biopharma Employees
Cue Biopharma had 41 employees as of December 31, 2024. The number of employees decreased by 12 or -22.64% compared to the previous year.
Employees
41
Change (1Y)
-12
Growth (1Y)
-22.64%
Revenue / Employee
$194,902
Profits / Employee
-$989,854
Market Cap
68.57M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
CUE News
- 8 days ago - Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer - GlobeNewsWire
- 22 days ago - Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies - GlobeNewsWire
- 4 weeks ago - Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease - GlobeNewsWire
- 2 months ago - Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - Cue Biopharma to Host Virtual Investor Event on May 15, 2025 - GlobeNewsWire
- 2 months ago - Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference - GlobeNewsWire
- 3 months ago - Cue Biopharma, Inc. (CUE) Business Update Call (Transcript) - Seeking Alpha
- 3 months ago - Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases - GlobeNewsWire